Table 1 Antibody panel used in the study

From: CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients

Antibodies

m/p

Clone

Source

Dilution/ml (μg)

Pretreatment a

CD117

p

—

DAKO, Glostrup, Denmark

10

—

 

p

—

Santa Cruz Biotechnology, Santa Cruz, CA, USA

10

—

Ki-67 antigen

m

MIB-1

Immunotech, Marseille, France

2.5

MWO-EDTA

CD34

m

QBEnd/10

Novocastra Laboratories, Newcastle upon Tyne, UK

2.5

MWO-CB

p21/Waf1

m

4D10

”

25

MWO-CB

Cyclin-E

m

13A3

”

20

MWO-EDTA

p53

m

DO7

”

1

MWO-CB

Fascin

m

IM20

”

2.5

MWO-EDTA

Her-2

p

—

DAKO, Glostrup, Denmark

0.6

MWO-EDTA

p27/Kip1

m

57

Transduction Laboratories, Lexington, KY, USA

0.4

MWO-CB

Chromogranin A

m

LK2H10

Signet Laboratories, Dedham, MA, USA

25

—

Synaptophysin

m

SY38

DAKO, Glostrup, Denmark

50

MWO-CB

Bcl-2

m

124

DAKO, Glostrup, Denmark

5

MWO-CB

  1. m, monoclonal; p, polyclonal;
  2. MWO-CB: microwave oven at 750 W for 10 min in citrate buffer, pH6; MWO-EDTA: microwave oven at 750 W for 12 min in ethylenediamine tetraacetic acid buffer, pH8.
  3. aAll pretreatments for antigen retrival were optimized according to internal standarization of the author's laboratory.
Back to article page